Publications found:
73,128
Sort by:
Competitor Analysis: Novel Mitotic Kinase Inhibitors
US$ 550.00
... cell cycle, whereas CDK7 has dual roles as a CDK-activating kinase (CAK) and a regulator of the transcriptional machinery. CDK8 and CDK9 ... Inhibitors Corporate Novel Mitotic Kinase Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, ...
September 2011
62 pages
Competitor Analysis: Her2 and Her3 Receptor Antagonists
US$ 413.00
... active projects in research and development of molecules targeting the Her2 (ErbB2) and Her3 receptor. In addition, the report lists company-specific ... Antagonists Pan-Her Receptor Antagonists Corporate Her2 and Her3 Receptor Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The ...
September 2011
63 pages
Competitor Analysis: EGF-R Agonists and Antagonists
US$ 533.00
... -R and Her2 Receptor Antagonists Pan-ErbB (pan-Her) Receptor Antagonists Multi-Target EGF-R Antagonists Others Corporate EGF-R Agonist and Antagonist R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about ...
September 2011
73 pages
Therapeutic Apheresis: Market Research Report
US$ 4,500.00
This report analyzes the US market for Therapeutic Apheresis in US$ Thousand by the following procedures: Photopheresis, Plasmapheresis, Erythrocytapheresis, Plateletpheresis, Leukapheresis, and Lipidpheresis. The specific end-use segments analyzed are Neurology Disorders, Hematology & Oncology Disorders, ...
September 2011
126 pages
Apoptosis: Market Research Report
US$ 4,200.00
This report analyzes the worldwide markets for Apoptosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia ... Pte Ltd., S*BIO Pte Ltd, TopoTarget A/S, Xigen SA, and ?terna Zentaris GmbH. Market data and analytics are derived from primary and secondary research ...
September 2011
617 pages
Enteral Feeding Pumps: Market Research Report
US$ 4,200.00
This report analyzes the worldwide markets for Enteral Feeding Pumps in US$ Million. The report provides separate comprehensive analytics for the US ... AG, Moog Inc., Nestle HealthCare Nutrition, and Nutricia Advanced Medical Nutrition. Market data and analytics are derived from primary and secondary research. ...
September 2011
190 pages
Healthcare Antimicrobial Plastics: Market Research Report
US$ 4,200.00
This report analyzes the worldwide markets for Healthcare Antimicrobial Plastics in Metric Tons. The report provides separate comprehensive analytics for the US, ... International Ltd., PolyChem Alloy, Inc., Sciessent LLC, and Troy Corporation. Market data and analytics are derived from primary and secondary ...
September 2011
348 pages
PHARMASSET - Another Step Towards Success!
US$ 90.00
Pharmasset (VRUS) announced top line data of PSI-7977 PhIIb, PROTON ... read our report released on 13th September, 2011 on VRUS titled “Another Step Towards Success”.
September 2011
4 pages
New Research into Prescribing Practices
US$ 695.00
Every day, doctors make hundreds of decisions. Decisions that affect patient care, diagnosis, follow up and pharmaceuticals prescribed.
What influences those choices? When it comes to prescri...
August 2011
43 pages
Creating Compelling Market Access Stories
US$ 495.00
Who's in charge? It's an increasingly complex question faced by pharma companies when it comes to creating compelling value stories for payers. With governments tightening purse strings, generics flo...
August 2011
43 pages
Extremities Market Report: 2011 Edition
US$ 700.00
... for a major share. The present report analyzes the global extremity market. The US extremity market is also presented in the report. The report analyzes the major growth drivers ...
August 2011
40 pages
Global Atrial Fibrillation Market Report: 2011 Edition
US$ 700.00
... is particularly significant. The report provides an analysis of the global atrial fibrillation market. It also discusses major trends, growth drivers and developments in atrial fibrillation market. The report also presents the ...
August 2011
32 pages
The para-Amino Phenol Industry in China
US$ 7,448.00
... by the demand from the downstream products especially paracetamol, para-aminophenol (PAP) industry in China keeps developing in recent years. The output of PAP ... 2010 Introduction to PAP production methods Forecast on supply and demand of in China, 2011-2015 Besides, compared with the last edition finished ...
August 2011
59 pages
External Defibrillator market in India 2011
US$ 950.00
... description of the segments in the defibrillator market in India. The market overview section provides an insight into the market and highlights the market size and growth. Import ...
August 2011
32 pages
Intravenous (IV) Solutions: Market Research Report
US$ 4,800.00
This report analyzes the worldwide markets for Intravenous (IV) Solutions in US$ Million. The report provides separate comprehensive analytics for the US, Canada ... ., Sino-Swed Pharmaceutical, Terumo Corporation, and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary ...
August 2011
274 pages
Overactive Bladder (OAB) Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Overactive Bladder (OAB) Therapeutics in US$ Million. The report provides separate comprehensive analytics for ... ., SALVAT Biotech, Sepracor Pharmaceuticals, Inc., and Watson Pharmaceuticals, Inc. Market data and analytics are derived from primary and secondary ...
August 2011
279 pages
Irritable Bowel Syndrome (IBS) Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Irritable Bowel Syndrome (IBS) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year ...
August 2011
433 pages
Stroke Prevention in Atrial Fibrillation - View on Upcoming Milestones
US$ 90.00
DETAILED DATA FROM ARISTOTLE STUDY AT ESC – AUGUST 28th. BMY is likely to announce detailed data on Eliquis in SPAF from the ARISTOTLE study. The data on Eliquis from ARISTOTLE will be compared to the data on Pradaxa from RELY trial and not Xarelto- ROCKET AF, as there are major differences in trial design. ...
August 2011
2 pages
Eisai - Catalysts Too Weak to Mitigate Key Patent Expiries
US$ 140.00
... Nov-10 and May-13 respectively); together they contributed ~56% of revenue in FY 03/11. Eisai solely depends on catalysts coming out of its pipeline. Following Halaven approval ... , Eisai has three late stage candidates E-2007/ perampanel ...
August 2011
8 pages
Roche, BMY - Zelboraf (Vemurafenib) approval- Competition to YERVOY starts
US$ 90.00
The USFDA approval of Zelboraf (Vemurafenib) for inoperable metastatic melanoma, well in advance of the PDUFA date is encouraging. USFDA has also approved the cobas BRAF mutation diagnostic test. This will reduce YERVOY uptake directly as ~50% of Metastatic Melanoma patients are B-RAF positive and Zelboraf ...
August 2011
2 pages
Gilead - Complera Approval - Positive Long Term Impact
US$ 90.00
Approval of Complera (GILD’s Truvada + Tibotec’s Edurant) reiterates GILD’s ... HIV infection. With the current economic turmoil, approval of once-daily Complera (formerly Fixed Dose Combination drug) impact may ... report released on 12th August, 2011, titled – “Complera Approval - Positive Long Term Impact”
August 2011
5 pages
Ranbaxy - When Will The Base Business Stabilize?
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after the Q2 CY11 result that was in line with our ... about a possible timely launch. Longer term potential of Ranbaxy seems promising with Daiichi-Ranbaxy likely to become the largest generic company in Japan ...
August 2011
6 pages
Cipla - Margin Improvement - A Healthy Sign.
US$ 140.00
... higher than our earnings estimate owing to the sharp improvement in gross margin. The improvement in gross margin (up by 330 bps, Y-o-Y) is largely due to the ... day exclusivity and (2) improvement in margin as contribution from Indore facility increases. For the longer term, CIPLA’s traditional business model ...
August 2011
6 pages
Celgene - Global Share Gains Continue + Pipeline Potential
US$ 140.00
... all commercial metrics – global share and duration gains, continued expansion of market ... access through approvals and reimbursements in the US and international market, and noteworthy operating efficiency places Celgene ... – “Global Share Gains Continue + Pipeline Potential”.
August 2011
6 pages
IPCA- Margin Improvement, Despite Lower Domestic Sales
US$ 140.00
... sales in WHO member countries. We expect several growth drivers for Ipca in the near term. (1) US generics growth even without the ... WHO member countries and branded formulations (3) margin improvement as sales mix improves in favor of formulation sales. We see Ipca as the best bet in the domestic formulations ...
August 2011
5 pages
TAKEDA - Multiple Challenges Blur Future!
US$ 140.00
There are three major concerns for Takeda – 1) Takeda has got European exposure by the Nycomed acquisition, but as both ... is expected. 2) Safety related issues with Actos affects market prospects of Takeda’s key candidate Aloglipin’s combination drug with Actos and, 3) Pipeline ...
August 2011
8 pages
China Freeze Drying System Industry Report, 2011 - 2012
US$ 1,600.00
With the rapid development of pharmaceutical industry in China, the market size of freeze drying equipment continuously expands, which reached RMB2.425 billion in 2009, including the market of cleanin...
August 2011
53 pages
Dishman - Moving away from CRAMS
US$ 140.00
Dishman’s Q1 FY12 result was below our expectations ... Amcis. The standalone EBITDA increased largely driven by sales from disinfectants in India, supply of intermediate of Brilinta to Astra Zeneca and ... most of them (except for Brilinta intermediate supply) coming from its non-CRAM business. On CRAMs part, we see ...
July 2011
5 pages
Lupin - Impact of Thin Pipeline Showing Up
US$ 140.00
... reiterate our Underperform with target price of `360 on Lupin after its Q1FY12 result that reflected a reduction in ... fag end of the quarter impacted the overall performance. We have always remained concerned about Lupin’s thin US pipeline along with a ... higher depreciation to eat into the earnings of Lupin.
July 2011
8 pages
Global Protein Therapeutics Market Analysis
US$ 1,800.00
Single User PDF Format: US$ 1,800.00
Multi-User License: US$ 2,800.00
Hard Copy: US$ 2,200.00
CD-ROM: US$ 2,200.00 Within the global pharmaceutical industry, protein therapeutics has b...
July 2011
180 pages
US e-health Market Analysis
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,500.00
Hard Copy: US$ 1,100.00
CD-ROM: US$ 1,100.00 The US represents one of the most developed healthcare markets global...
July 2011
75 pages
Competitor Analysis: Heat shock protein 90 (Hsp90) Inhibitors
US$ 275.00
... The present Competitive Intelligence report about Heat shock protein 90 (Hsp90) Inhibitors provides a competitor evaluation in the field of novel small molecules ... database will be sent by e-mail and allow online work with the project data to print or export an individual report. Inhibition of heat shock ...
July 2011
26 pages
Competitor Analysis: HDAC Inhibitors
US$ 550.00
... the database will be sent by e-mail and allow online work with the project data to print or export an individual report. Histone deacetylase (HDAC) ... class I and II Inhibitors Multi-Target HDAC Inhibitors Others Corporate HDAC Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series: The ...
July 2011
58 pages
Regeneron - Entering the Commercial TRAP
US$ 140.00
... US next month (PDUFA: August, 20). What are the risks to its commercial success and future of REGN’s pipeline? A comprehensive analysis about the ...
July 2011
7 pages
CADILA HEALTHCARE LTD - In a Consolidation Phase
US$ 140.00
CDH’s Q1 FY12 adjusted result (adjusted to the milestone income from Abbott) was below our sales and earnings estimate. Higher base created in FY11 by pushing product sales last year to achieve the $1b sales mark was the main reason for a muted performance in most of the business divisions. While the ...
July 2011
6 pages
Novartis vs. Peer group- Growth rate differential to widen going forward
US$ 90.00
Novartis reported solid revenue growth driven by Sandoz, recently launched products and Alcon Acquisition. Going ... shape up in the longer term. Novartis is in better position to return back profits to investors compare to its global peers in unfavorable environment mainly due to its ...
July 2011
2 pages
Mixed CARE-MS I data – Good for BIIB!
US$ 90.00
... (EDSS) was not achieved (vs. reduction of 91% in PhII data at 36 months) in its pivotal PhIII trial – CARE-MS I. What does this bode for other players ... ? Please read our report, released on 11th July, 2011, titled – “Mixed CARE-MS I data – Good for BIIB!”
July 2011
4 pages
